ReviewJournal of perinatology : official journal of the California Perinatal Association2026
The role of early administration of erythropoiesis-stimulating agents in preterm neonatal neuroprotection: a systematic review and meta-analysis.
Review in Journal of perinatology : official journal of the California Perinatal Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrematurity remains a leading cause of neonatal mortality and morbidity; with neurodevelopmental disorders among its most significant complications. Erythropoiesis-stimulating agents (ESAs) have been explored for their neuroprotective potential.
objectiveTo evaluate whether early prophylactic administration of ESAs in preterm neonates ( < 37 weeks' gestation) improves neurodevelopmental outcomes up to 36 months of age. STUDY
designA systematic search of MEDLINE, Embase, Cochrane Library, and ICTRP identified 1142 studies, of which ten met the inclusion criteria. The meta-analysis included only randomized control trials (RCTs) reporting Bayley Scales of Infant Development scores or cerebral palsy diagnosis.
resultsAmong the ten included studies (eight RCTs, two retrospective cohorts), comprising 2861 preterm infants, narrative synthesis was inconclusive. Meta-analysis showed reduced odds of adverse cognitive outcomes (OR: 0.55; 95% CI: 0.35-0.85), and cerebral palsy (OR: 0.66; 95% CI: 0.45-0.97) in ESA-treated group, with no evidence of publication bias. Sensitivity analyses indicated potential fragility of pooled estimates.
conclusionΕarly ESAs administration may provide cognitive benefits. Standardized methodologies and longer-term studies are needed to confirm neurodevelopmental effects and clinical relevance.
Identifiers
42032166What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.